Trade Report: The Astrazeneca PLC’s (AZN) Hold Rating Reaffirmed at Leerink Swann

The Astrazeneca PLC’s (AZN) Hold Rating Reaffirmed at Leerink Swann

Leerink Swann restated their hold rating on shares of Astrazeneca PLC (NYSE:AZN) in a research note issued to investors on Sunday. The brokerage currently has a $35.00 price target on the stock.

AZN has been the subject of several other reports. Bank of America Corp. set a $41.40 price objective on shares of Astrazeneca PLC and gave the stock a buy rating in a research note on Thursday, September 8th. Argus upgraded shares of Astrazeneca PLC from a hold rating to a buy rating and set a $38.00 price objective for the company in a research note on Monday, August 29th. Piper Jaffray Cos. began coverage on shares of Astrazeneca PLC in a report on Friday, September 23rd. They set an overweight rating for the company. BNP Paribas cut shares of Astrazeneca PLC from an outperform rating to a neutral rating in a report on Tuesday, September 13th. Finally, Berenberg Bank reissued a buy rating on shares of Astrazeneca PLC in a report on Sunday, September 11th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of Buy and a consensus price target of $37.56.

Astrazeneca PLC (NYSE:AZN) opened at 32.29 on Friday. The company has a 50-day moving average of $33.23 and a 200 day moving average of $30.79. Astrazeneca PLC has a one year low of $26.97 and a one year high of $35.04. The company has a market cap of $81.69 billion, a P/E ratio of 36.90 and a beta of 0.75.

Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.83 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The business earned $5.60 billion during the quarter, compared to the consensus estimate of $5.56 billion. During the same period in the previous year, the firm posted $1.21 earnings per share. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. Analysts anticipate that Astrazeneca PLC will post $2.97 earnings per share for the current year.

The company also recently announced a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were issued a $0.44 dividend. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s payout ratio is 78.29%.

A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its position in Astrazeneca PLC by 0.3% in the first quarter. JPMorgan Chase & Co. now owns 2,325,462 shares of the company’s stock valued at $65,485,000 after buying an additional 6,027 shares during the last quarter. Integrated Investment Consultants LLC raised its position in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock valued at $144,000 after buying an additional 275 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in Astrazeneca PLC by 3.1% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 34,217 shares of the company’s stock valued at $964,000 after buying an additional 1,027 shares during the last quarter. Fisher Asset Management LLC raised its position in Astrazeneca PLC by 45.2% in the second quarter. Fisher Asset Management LLC now owns 338,979 shares of the company’s stock valued at $10,159,000 after buying an additional 105,570 shares during the last quarter. Finally, Garrison Financial Corp raised its position in Astrazeneca PLC by 1.1% in the second quarter. Garrison Financial Corp now owns 18,992 shares of the company’s stock valued at $573,000 after buying an additional 205 shares during the last quarter. Institutional investors own 11.39% of the company’s stock.

About Astrazeneca PLC

Related posts

Leave a Comment